Analysis: Julie Johnson's sell of MDT (Medtronic plc)
Assessment: Low signal
An unactionable, stale sale of Medtronic plc that fits a high-churn, adviser-managed baseline with no committee alignment or corroborating signals.
- Member: Julie Johnson
- Party / state: Democratic-TX-32
- Chamber: House
- Transaction: Sell
- Amount: $1,001 - $15,000
- Ticker: MDT
- Company: Medtronic plc
- Trade date: 2025-05-07
- Disclosure date: 2026-08-05
- Disclosure lag: 455 days
Executive summary
The analyzed transaction is a sale of Medtronic plc (MDT) by House member Julie Johnson on 2025-05-07 (reported amount range $1,001-$15,000), disclosed on 2026-08-05 (455-day lag). Within the SEC context window around the trade, Medtronic filed an 8-K on 2025-05-21 reporting Q4/FY2025 results and announcing intent to separate its Diabetes business, based on SEC primary documents. Broader congressional, regulatory, and government-contract context could not be retrieved in this environment due to access limitations to Congress.gov, Federal Register, Regulations.gov, and USAspending.gov.
From the user-provided trading history, MDT appears only as sales (4 total) by the member, with the first sale on 2025-05-07 and additional sales later in 2025; no MDT purchases were present in the provided dataset. The reported trade size for MDT matches the member’s most common disclosed range ($1,001-$15,000) across a high-volume trading dataset (574 trades across 231 tickers during 2025-01-15 to 2026-05-12). The disclosure lag for the analyzed MDT sale is 455 days based on the provided trade date and filed date. In SEC filings near the analyzed trade date, Medtronic filed an 8-K on 2025-05-21 (14 days after the member’s 2025-05-07 sale) that included a press release on Q4/FY2025 results and a separate press release announcing intent to separate the Diabetes business, both hosted on SEC EDGAR. In the provided Form 4 window (2025-04-07 to 2025-06-06), insider reports were primarily equity awards/grants (code A), tax-related withholdings (code F), and one gift (code G); no open-market purchase (P) or sale (S) transactions were included in the provided dataset.
Timeline
- 2025-02-18 — Medtronic filed an 8-K (Items 2.02, 9.01) containing Q3 FY2025 financial results press release (Exhibit 99.1). The exhibit text includes a statement that CMS announced coverage for Renal Denervation expected to become final on or before October 11, 2025.
- 2025-03-17 — Medtronic filed an 8-K (Item 5.02).
- 2025-04-28 — Multiple Form 4 filings report director and officer equity grants/awards (transaction code A) dated 2025-04-28 (examples included in insider_activity_findings).
- 2025-04-29 — Multiple Form 4 filings report tax withholding or payment transactions (transaction code F) dated 2025-04-29 (examples included in insider_activity_findings).
- 2025-05-07 — Julie Johnson reported selling MDT (Medtronic plc), amount range $1,001-$15,000, owner: self.
- 2025-05-21 — Medtronic filed an 8-K (Items 2.02, 5.02, 8.01, 9.01) with exhibits including Q4/FY2025 results press release and a press release announcing intent to separate the Diabetes business.
- 2025-06-03 — Form 4 reports a gift transaction (code G) by Chief Accounting Officer Denise L. Blomquist dated 2025-06-03.
- 2026-08-05 — Disclosure filing date for the analyzed trade.
Independent analysis of public financial disclosures. Not financial or investment advice.